Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune respons...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/3/382 |
| _version_ | 1797441224532033536 |
|---|---|
| author | Eleni Papadokostaki Anastasios Tentolouris Ioanna A. Anastasiou Mina Psichogiou Evangelia Iliaki Ioanna Eleftheriadou Angelos Hatzakis Nikolaos Tentolouris |
| author_facet | Eleni Papadokostaki Anastasios Tentolouris Ioanna A. Anastasiou Mina Psichogiou Evangelia Iliaki Ioanna Eleftheriadou Angelos Hatzakis Nikolaos Tentolouris |
| author_sort | Eleni Papadokostaki |
| collection | DOAJ |
| description | The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune response in participants with and without DM after vaccination with the BNT162b2 mRNA vaccine. A total of 174 participants (58 with and 116 without diabetes, matched for age) were included. Antibodies were measured 21 days after the first dose, 7–15 days after the second dose, and 70–75 days after the second and before the third dose of the vaccine. Antibodies were measured by an anti-SARS-CoV-2 receptor-binding domain IgG (Abs-RBD-IgG) assay by a chemiluminescent microparticle immune assay; values > 50 AU/mL are considered protective from severe disease. Almost 17% of participants with DM did not develop adequate humoral immune response to the BNT162b2 mRNA vaccine after the first dose; however, it was high and similar after the second dose in both participants with and without DM and remained so almost 2 months after the second dose of the vaccine. Geometric mean values of Abs-RBD-IgG were not significantly different between participants with and without DM during the study. At least two doses of the BNT162b2 vaccine are necessary to ensure adequate and sustainable immune response in people with DM. |
| first_indexed | 2024-03-09T12:19:56Z |
| format | Article |
| id | doaj.art-860f19eb4ecf4195892cf43a36cb75c9 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T12:19:56Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-860f19eb4ecf4195892cf43a36cb75c92023-11-30T22:42:10ZengMDPI AGVaccines2076-393X2022-03-0110338210.3390/vaccines10030382Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational StudyEleni Papadokostaki0Anastasios Tentolouris1Ioanna A. Anastasiou2Mina Psichogiou3Evangelia Iliaki4Ioanna Eleftheriadou5Angelos Hatzakis6Nikolaos Tentolouris7Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceDiabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceDiabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceFirst Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceMicrobiology Department, General Hospital of Heraklion, Venizeleio, 714 09 Heraklion, GreeceDiabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, GreeceDiabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceThe mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune response in participants with and without DM after vaccination with the BNT162b2 mRNA vaccine. A total of 174 participants (58 with and 116 without diabetes, matched for age) were included. Antibodies were measured 21 days after the first dose, 7–15 days after the second dose, and 70–75 days after the second and before the third dose of the vaccine. Antibodies were measured by an anti-SARS-CoV-2 receptor-binding domain IgG (Abs-RBD-IgG) assay by a chemiluminescent microparticle immune assay; values > 50 AU/mL are considered protective from severe disease. Almost 17% of participants with DM did not develop adequate humoral immune response to the BNT162b2 mRNA vaccine after the first dose; however, it was high and similar after the second dose in both participants with and without DM and remained so almost 2 months after the second dose of the vaccine. Geometric mean values of Abs-RBD-IgG were not significantly different between participants with and without DM during the study. At least two doses of the BNT162b2 vaccine are necessary to ensure adequate and sustainable immune response in people with DM.https://www.mdpi.com/2076-393X/10/3/382humoral immune responseSARS-CoV-2COVID-19vaccineantibodies |
| spellingShingle | Eleni Papadokostaki Anastasios Tentolouris Ioanna A. Anastasiou Mina Psichogiou Evangelia Iliaki Ioanna Eleftheriadou Angelos Hatzakis Nikolaos Tentolouris Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study Vaccines humoral immune response SARS-CoV-2 COVID-19 vaccine antibodies |
| title | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
| title_full | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
| title_fullStr | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
| title_full_unstemmed | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
| title_short | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
| title_sort | immunogenicity of sars cov 2 bnt162b2 vaccine in people with diabetes a prospective observational study |
| topic | humoral immune response SARS-CoV-2 COVID-19 vaccine antibodies |
| url | https://www.mdpi.com/2076-393X/10/3/382 |
| work_keys_str_mv | AT elenipapadokostaki immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT anastasiostentolouris immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT ioannaaanastasiou immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT minapsichogiou immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT evangeliailiaki immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT ioannaeleftheriadou immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT angeloshatzakis immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT nikolaostentolouris immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy |